Improved survival for patients with advanced neuroblastoma after high-dose combined chemotherapy based in part on N-myc amplification

Journal of Pediatric Surgery

Volumn 35, Issue 12, 2000, Pages 1737-1741

  Suita, S ^{a,b,c,d,e,f,g,h,i,j}   Tajiri, T ^{a,b,c,d,e,f,g,h,i,j}   Sera, Y ^{a,b,c,d,e,f,g,h,i,j}   Takamatsu, H ^{a,b,c,d,e,f,g,h,i,j}   Mizote, H ^{a,b,c,d,e,f,g,h,i,j}   Nagasaki, A ^{a,b,c,d,e,f,g,h,i,j}   Kurosaki, N ^{a,b,c,d,e,f,g,h,i,j}   Hara, T ^{a,b,c,d,e,f,g,h,i,j}   Okamura, J ^{a,b,c,d,e,f,g,h,i,j}   Miyazaki, S ^{a,b,c,d,e,f,g,h,i,j}   Sugimoto, T ^{a,b,c,d,e,f,g,h,i,j}   Kawakami, K ^{a,b,c,d,e,f,g,h,i,j}   Eguchi, H ^{a,b,c,d,e,f,g,h,i,j}   Tsuneyoshi, M ^{a,b,c,d,e,f,g,h,i,j}  

^a Committee for Pediatric Solid Malignant Tumors In the Kyushu Area ^*  (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

^e KURUME UNIVERSITY   (Japan)

^f FUKUOKA CHILDREN S HOSPITAL   (Japan)

^g NAGASAKI UNIVERSITY   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ SAGA UNIVERSITY   (Japan)

^j UNIVERSITY OF MIYAZAKI   (Japan)

more..

Author keywords

Chemotherapy; N myc; Neuroblastoma

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; TENIPOSIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; ONCOGENE C MYB; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 0033663134     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2000.19236     Document Type: Article

References (17)

1. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma
2. Follow-up studies on pediatric solid tumors, registered between 1981-1985
3. Improved survival rates in children over 1 year of age with stage III or IV Neuroblastoma following an intensive chemotherapeutic regimen
4. What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification: A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma
5. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: Amplified or not amplified?
6. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group Study
7. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status
8. Clinical evaluation of sequentially scheduled cisplatin and VM-26 in neuroblastoma: Response and toxicity
9. Preoperative high dose cyclophosphamide treatment for the patients with advanced neuroblastoma
10. Amplification of N-myc in untreated human neuroblastoma correlates with advanced stage disease
11. Association of multiple copies of N-myc oncogene with rapid progression of neuroblastomas
12. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
13. Treatment combined with bone marrow transplantation for advanced neuroblastoma: An analysis patients who pretreated intensively with the protocol of the study group of Japan
14. Stage IV neuroblastoma with MRSA-related enterocolitis at the time of myelosuppression by the intensive chemotherapy
15. Effect of CPT-11 (a unique topoisomerase I inhibitor) on a highly malignant xenotransplanted neuroblastoma
16. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
17. A phase I/IB trial of murine monoclonalanti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group